5ek0

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (06:31, 5 July 2023) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
 +
==Human Nav1.7-VSD4-NavAb in complex with GX-936.==
==Human Nav1.7-VSD4-NavAb in complex with GX-936.==
-
<StructureSection load='5ek0' size='340' side='right' caption='[[5ek0]], [[Resolution|resolution]] 3.53&Aring;' scene=''>
+
<StructureSection load='5ek0' size='340' side='right'caption='[[5ek0]], [[Resolution|resolution]] 3.53&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[5ek0]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EK0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5EK0 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[5ek0]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Aliarcobacter_butzleri_RM4018 Aliarcobacter butzleri RM4018] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EK0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5EK0 FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5P2:3-CYANO-4-[2-[2-(1-ETHYLAZETIDIN-3-YL)PYRAZOL-3-YL]-4-(TRIFLUOROMETHYL)PHENOXY]-~{N}-(1,2,4-THIADIAZOL-5-YL)BENZENESULFONAMIDE'>5P2</scene>, <scene name='pdbligand=PX4:1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE'>PX4</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.53&#8491;</td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ek0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ek0 OCA], [http://pdbe.org/5ek0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ek0 RCSB], [http://www.ebi.ac.uk/pdbsum/5ek0 PDBsum]</span></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5P2:3-CYANO-4-[2-[2-(1-ETHYLAZETIDIN-3-YL)PYRAZOL-3-YL]-4-(TRIFLUOROMETHYL)PHENOXY]-~{N}-(1,2,4-THIADIAZOL-5-YL)BENZENESULFONAMIDE'>5P2</scene>, <scene name='pdbligand=PX4:1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE'>PX4</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5ek0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ek0 OCA], [https://pdbe.org/5ek0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5ek0 RCSB], [https://www.ebi.ac.uk/pdbsum/5ek0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5ek0 ProSAT]</span></td></tr>
</table>
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/SCN9A_HUMAN SCN9A_HUMAN] Channelopathy-associated congenital insensitivity to pain;Dravet syndrome;Primary erythromelalgia;Sodium channelopathy-related small fiber neuropathy;Generalized epilepsy with febrile seizures-plus;Hereditary sensory and autonomic neuropathy type 2;Paroxysmal extreme pain disorder;Erythromelalgia. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/A8EVM5_ALIB4 A8EVM5_ALIB4] [https://www.uniprot.org/uniprot/SCN9A_HUMAN SCN9A_HUMAN] Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient (PubMed:7720699, PubMed:17167479, PubMed:25240195, PubMed:26680203, PubMed:15385606, PubMed:16988069, PubMed:17145499, PubMed:19369487, PubMed:24311784). It is a tetrodotoxin-sensitive Na(+) channel isoform (PubMed:7720699). Plays a role in pain mechanisms, especially in the development of inflammatory pain (PubMed:17167479, PubMed:17145499, PubMed:19369487, PubMed:24311784).<ref>PMID:15178348</ref> <ref>PMID:15385606</ref> <ref>PMID:16988069</ref> <ref>PMID:17145499</ref> <ref>PMID:17167479</ref> <ref>PMID:19369487</ref> <ref>PMID:24311784</ref> <ref>PMID:25240195</ref> <ref>PMID:26680203</ref> <ref>PMID:7720699</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Voltage-gated sodium (Nav) channels propagate action potentials in excitable cells. Accordingly, Nav channels are therapeutic targets for many cardiovascular and neurological disorders. Selective inhibitors have been challenging to design because the nine mammalian Nav channel isoforms share high sequence identity and remain recalcitrant to high-resolution structural studies. Targeting the human Nav1.7 channel involved in pain perception, we present a protein-engineering strategy that has allowed us to determine crystal structures of a novel receptor site in complex with isoform-selective antagonists. GX-936 and related inhibitors bind to the activated state of voltage-sensor domain IV (VSD4), where their anionic aryl sulfonamide warhead engages the fourth arginine gating charge on the S4 helix. By opposing VSD4 deactivation, these compounds inhibit Nav1.7 through a voltage-sensor trapping mechanism, likely by stabilizing inactivated states of the channel. Residues from the S2 and S3 helices are key determinants of isoform selectivity, and bound phospholipids implicate the membrane as a modulator of channel function and pharmacology. Our results help to elucidate the molecular basis of voltage sensing and establish structural blueprints to design selective Nav channel antagonists.
 +
 +
Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.,Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez JC, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J Science. 2015 Dec 18;350(6267):aac5464. doi: 10.1126/science.aac5464. PMID:26680203<ref>PMID:26680203</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 5ek0" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Ahuja, S]]
+
[[Category: Aliarcobacter butzleri RM4018]]
-
[[Category: Koth, C M]]
+
[[Category: Homo sapiens]]
-
[[Category: Mukund, S]]
+
[[Category: Large Structures]]
-
[[Category: Payandeh, J]]
+
[[Category: Ahuja S]]
-
[[Category: Starovasnik, M A]]
+
[[Category: Koth CM]]
-
[[Category: Ion channel]]
+
[[Category: Mukund S]]
-
[[Category: Membrane protein]]
+
[[Category: Payandeh J]]
-
[[Category: Metal transport]]
+
[[Category: Starovasnik MA]]
-
[[Category: Small molecule antagonist]]
+
-
[[Category: Voltage-gated sodium channel]]
+

Current revision

Human Nav1.7-VSD4-NavAb in complex with GX-936.

PDB ID 5ek0

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/5ek0"
Personal tools